Pre-hospital ECMO or Conventional Resuscitation for Refractory Cardiac Arrest
Launched by AUSTRALIAN AND NEW ZEALAND INTENSIVE CARE RESEARCH CENTRE · Dec 11, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treating patients who experience a cardiac arrest outside of the hospital, specifically focusing on those who do not respond to standard resuscitation efforts. The trial will compare two methods: one group of patients will receive a special type of advanced life support called Extracorporeal Cardiopulmonary Resuscitation (ECPR) before reaching the hospital, while another group will receive the usual care. Researchers aim to see how many patients can be successfully treated with each method.
To be eligible for this study, participants need to be adults aged 18 to 70 who have experienced a witnessed cardiac arrest and received CPR from bystanders. They should have been without a heartbeat for more than 20 minutes but less than 45 minutes, and their heart rhythm during the event should be one of several specific types. It’s important to note that individuals with certain severe health conditions or those who have an advance directive stating they do not wish to be resuscitated will not be included. If a participant is accepted into the trial, they will receive either the new treatment or standard care during the critical time before they arrive at the hospital.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients 18-70 years old
- • Witnessed cardiac arrest
- • Bystander CPR
- • Refractory cardiac arrest (\>20 mins, but \<45 mins)
- • Initial cardiac rhythm VF, VT or PEA
- • Within hours of PACER service operation (e.g. mon-fri 0800-1700)
- • Within 25 mins of rapid response ambulance (code 1 lights and sirens)
- Exclusion Criteria:
- • Initial cardiac rhythm asystole
- • ROSC with sustained recovery
- • Technically not possible to perform percutaneous cannulation
- * Evidence of/suspectedSignificant end stage disease:
- • Severe disability impairing activities of daily living
- • End-stage organ - cardiac, liver, lung, renal
- • Other life-limiting diseases e.g malignancy, terminal illness
- • Advance health care directive (not for resuscitation)
About Australian And New Zealand Intensive Care Research Centre
The Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) is a leading research organization dedicated to improving outcomes in critically ill patients through innovative clinical trials and research initiatives. Based at Monash University, the Centre fosters collaborative partnerships among clinicians, researchers, and institutions across Australia and New Zealand. Its focus on evidence-based practice and translational research aims to enhance the quality of intensive care, drive advancements in treatment protocols, and ultimately improve patient care in the intensive care unit (ICU) setting. ANZIC-RC is committed to addressing key challenges in critical care medicine, ensuring that findings from its trials contribute to better health outcomes and inform clinical guidelines globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Sacha Richardson, MBBS
Principal Investigator
The Alfred
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported